1.
Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation
Acta Pharmaceutica Sinica B
;
(6): 3678-3682, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-922740
RESUMEN
EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19. To investigate the optimal parameters, EIDD-2801 was optimized